BIOMAT Database Logo BIOMAT Database Logo

Sequential treatment of metastatic breast cancer with tamoxifen after megestrol acetate therapy and vice versa (a retrospective study). 1985

J Alexieva-Figusch, and W L Van Putten, and H A van Gilse, and J Blonk-vd Wijst, and J G Klijn

The progestin megestrol acetate and the anti-estrogen tamoxifen are used as effective drugs in the treatment of metastatic breast cancer and have few side effects. The sequence and indications for use in practice still need to be defined. Of 219 postmenopausal patients with metastatic breast cancer and measurable lesions, 136 were treated with megestrol acetate (MA) per os (180 mg daily) and followed by tamoxifen (TAM) (40 mg daily) in cases with progression, and 83 patients were treated with the inverse drug regimen. In the first line treatment they showed similar effects: MA caused remission in 31/136 patients (23%) and TAM in 17/80 patients (22%) (mean duration 12 and 13 months respectively), while as a second treatment line MA caused remission in 14/83 patients (17%) and TAM in 12/132 patients (9%), which was not significant (P = 0.10). Also with respect to survival there was no significant difference between the two treatment modalities.

UI MeSH Term Description Entries
D008535 Megestrol A progestational hormone used most commonly as the acetate ester. As the acetate, it is more potent than progesterone both as a progestagen and as an ovulation inhibitor. It has also been used in the palliative treatment of breast cancer. 17-Hydroxy-6-methylpregna-3,6-diene-3,20-dione,Pregna-4,6-diene-3,20-dione, 17-hydroxy-6-methyl-
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D013629 Tamoxifen One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM. ICI-46,474,ICI-46474,ICI-47699,Nolvadex,Novaldex,Soltamox,Tamoxifen Citrate,Tomaxithen,Zitazonium,Citrate, Tamoxifen,ICI 46,474,ICI 46474,ICI 47699,ICI46,474,ICI46474,ICI47699

Related Publications

J Alexieva-Figusch, and W L Van Putten, and H A van Gilse, and J Blonk-vd Wijst, and J G Klijn
Treatment of advanced breast cancer with megestrol acetate after therapy with tamoxifen.
February 1982, Cancer,
J Alexieva-Figusch, and W L Van Putten, and H A van Gilse, and J Blonk-vd Wijst, and J G Klijn
Cyclic sequential endocrine therapy for advanced breast cancer using a combination of tamoxifen and megestrol acetate.
October 1994, Oncology,
J Alexieva-Figusch, and W L Van Putten, and H A van Gilse, and J Blonk-vd Wijst, and J G Klijn
Randomized comparison of the effects of tamoxifen, megestrol acetate, or tamoxifen plus megestrol acetate on treatment response and survival in patients with metastatic breast cancer.
November 1993, Annals of oncology : official journal of the European Society for Medical Oncology,
J Alexieva-Figusch, and W L Van Putten, and H A van Gilse, and J Blonk-vd Wijst, and J G Klijn
Cyclic and sequential therapy with tamoxifen and medroxyprogesterone acetate in metastatic breast cancer.
August 1989, Journal of surgical oncology,
J Alexieva-Figusch, and W L Van Putten, and H A van Gilse, and J Blonk-vd Wijst, and J G Klijn
Endocrine effects of the combination of megestrol acetate and tamoxifen in the treatment of metastatic breast cancer.
September 1984, European journal of cancer & clinical oncology,
J Alexieva-Figusch, and W L Van Putten, and H A van Gilse, and J Blonk-vd Wijst, and J G Klijn
Megestrol acetate: a new role in the treatment of metastatic breast cancer.
April 1987, Seminars in hematology,
J Alexieva-Figusch, and W L Van Putten, and H A van Gilse, and J Blonk-vd Wijst, and J G Klijn
[Metastatic breast cancer: a comparative study of the efficacy of tamoxifen and the sequential administration of tamoxifen and medroxyprogesterone acetate].
January 1984, Bulletin du cancer,
J Alexieva-Figusch, and W L Van Putten, and H A van Gilse, and J Blonk-vd Wijst, and J G Klijn
Oral metronomic chemo-hormonal-therapy of metastatic breast cancer with cyclophosphamide and megestrol acetate.
June 2010, Journal of chemotherapy (Florence, Italy),
J Alexieva-Figusch, and W L Van Putten, and H A van Gilse, and J Blonk-vd Wijst, and J G Klijn
Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.
January 2003, Breast cancer research and treatment,
J Alexieva-Figusch, and W L Van Putten, and H A van Gilse, and J Blonk-vd Wijst, and J G Klijn
Megestrol acetate versus aminoglutethimide for metastatic breast cancer.
November 1989, Breast cancer research and treatment,
Copied contents to your clipboard!